Performance enhancement drugs: what they are, what they do, and what they cost

Performance enhancement drugs sit at an awkward intersection of legitimate medicine, human ambition, and—let’s be blunt—wishful thinking. I’ve interviewed clinicians who prescribe some of these medications for serious disease, and I’ve also met athletes and everyday gym-goers who treat the same substances like shortcuts. The problem is that the body doesn’t care what your intention was. Biology responds to chemistry, and chemistry has consequences.

In medical practice, a number of drugs that get labeled “performance enhancers” have real, evidence-based roles: treating anemia, delayed puberty, testosterone deficiency, severe muscle wasting, narcolepsy, attention disorders, or certain lung and heart conditions. In those settings, the goal is not “winning.” It’s restoring function, preventing complications, and improving quality of life. Outside of those settings, the same agents are often used to chase strength, speed, leanness, focus, or sexual performance—sometimes with no diagnosis, no monitoring, and no idea what’s actually in the vial or tablet.

This article is a practical, medically grounded guide to the landscape of performance enhancement drugs. We’ll sort out approved therapeutic uses from off-label use, and both from outright misuse. We’ll talk about the big categories—anabolic-androgenic steroids, stimulants, erythropoiesis-stimulating agents, growth hormone and related peptides, beta-2 agonists, and a few “gray-zone” compounds. We’ll also cover why effects are frequently exaggerated, why side effects are commonly minimized, and why the most dangerous outcomes tend to arrive quietly at first.

If you want a quick roadmap: start with what the drug is meant to treat, then ask what it does to normal physiology, then ask what happens when you push that physiology too far. That’s the thread I follow when patients tell me, “Doc, it’s just a cycle,” or “It’s only for a cut.” Human bodies are messy. They don’t read forum posts.

For related background on mental and behavioral drivers behind misuse, see our overview of common mental health issues.

Medical applications

“Performance enhancement drugs” is not a single medication. It’s a catch-all label applied to multiple therapeutic classes. Below are the most common categories, with their primary medical indications, established secondary uses, and where the evidence gets thin.

2.1 Primary indications (legitimate medical uses)

Anabolic-androgenic steroids (AAS) are synthetic derivatives of testosterone. The generic/international nonproprietary name depends on the compound—examples include testosterone (various esters), nandrolone, oxandrolone, stanozolol, and others. Their therapeutic class is anabolic-androgenic steroid (androgen receptor agonist). The primary use in modern medicine is narrower than most people assume: testosterone replacement for confirmed hypogonadism, certain delayed puberty scenarios, and selected catabolic states (for specific agents) under specialist care.

In clinic, when testosterone is prescribed appropriately, the intent is to normalize levels and relieve symptoms such as low libido, fatigue, reduced muscle mass, and low bone density in men with documented deficiency. That’s not the same thing as pushing levels above the physiologic range to chase rapid hypertrophy. Patients tell me they expected a movie-montage transformation. Instead they got acne, irritability, and lab abnormalities—plus disappointment when the “gains” didn’t match the hype.

Erythropoiesis-stimulating agents (ESAs) such as epoetin alfa and darbepoetin alfa (therapeutic class: erythropoiesis-stimulating agents; synthetic erythropoietin analogs) are used for anemia in specific contexts, particularly chronic kidney disease and chemotherapy-associated anemia. Their clinical value is straightforward: reduce transfusion requirements and improve anemia-related symptoms when used under guideline-based targets. In sport, the same biology is exploited to increase red blood cell mass and oxygen-carrying capacity. That “benefit” comes with a very real viscosity problem—thicker blood is not a harmless upgrade.

CNS stimulants include amphetamine salts, methylphenidate, and related agents (therapeutic class: central nervous system stimulants). The primary use is attention-deficit/hyperactivity disorder (ADHD) and, for some agents, narcolepsy. In those conditions, stimulants improve attention, reduce impulsivity, and support daytime functioning. In competitive environments, they’re sought for alertness, reaction time, appetite suppression, and perceived “drive.” I often see the downside first: insomnia, anxiety, elevated blood pressure, and a brittle sort of focus that collapses under stress.

Beta-2 agonists such as albuterol (salbutamol) and formoterol (therapeutic class: beta-2 adrenergic agonists) are cornerstone therapies for asthma and certain obstructive lung diseases. Their primary use is bronchodilation—relaxing airway smooth muscle to improve airflow. Some users chase a mild stimulant effect or fat-loss claims, and some combine them with other agents in “stacks.” From a medical perspective, that’s where palpitations and tremor stop being a nuisance and start being a warning.

Growth hormone (somatropin) (therapeutic class: recombinant human growth hormone) is prescribed for documented growth hormone deficiency, certain pediatric growth disorders, and specific wasting conditions. Its primary use is replacing a deficient hormone to support normal growth and metabolic function. Outside medicine, it’s marketed as a recomposition miracle. The reality is less glamorous: edema, joint pain, carpal tunnel symptoms, insulin resistance, and a lot of money spent for changes that are often subtler than promised.

PDE5 inhibitors such as sildenafil (brand names include Viagra; therapeutic class: phosphodiesterase-5 inhibitor) have a clear medical role in erectile dysfunction and, in specific formulations/contexts, pulmonary arterial hypertension. They’re sometimes lumped into “performance enhancement drugs” because they affect sexual performance and because some athletes experiment with them for altitude or endurance myths. The physiology is real—nitric oxide signaling and smooth muscle relaxation—but the leap from mechanism to meaningful athletic advantage is where people get carried away.

2.2 Approved secondary uses (where applicable)

Some agents in this space have secondary approved uses that are legitimate yet frequently misunderstood.

• Testosterone is used in certain gender-affirming care protocols under specialized supervision, and in some delayed puberty contexts. The goal is physiologic alignment and symptom relief, not supraphysiologic enhancement.
• Sildenafil and related PDE5 inhibitors have an approved role in pulmonary arterial hypertension (in appropriate dosing forms and under specialist care). That’s a cardiopulmonary disease state, not a “better cardio” hack.
• Somatropin is used for specific pediatric indications and certain wasting syndromes; it is not an anti-aging cosmetic drug in any evidence-based sense.

When people read a list of indications online, they often miss the context: diagnosis criteria, monitoring, contraindications, and the fact that “approved” does not mean “safe for anyone.” On a daily basis I notice that most harm comes from skipping the boring parts—baseline labs, follow-up, and honest disclosure of what else is being taken.

2.3 Off-label uses (clearly off-label)

Off-label prescribing is common in medicine, but it requires a careful risk-benefit discussion and monitoring. In the performance-enhancement world, “off-label” is frequently used as a polite label for experimentation.

• Oxandrolone has been used in selected catabolic states and severe weight loss under specialist care; outside that context it is widely misused for physique goals.
• Clomiphene citrate (a selective estrogen receptor modulator; brand name Clomid) is sometimes used off-label in men with certain infertility patterns or secondary hypogonadism to stimulate endogenous testosterone production. In gym culture it is often used without evaluation of pituitary-gonadal function and without attention to vision side effects or mood changes.
• Metformin (biguanide; brand name Glucophage) is occasionally used off-label in insulin resistance contexts beyond type 2 diabetes, but using it as a “cutting” drug without medical indication is a great way to collect GI misery and miss the real issue.

If you’re reading this and thinking, “But everyone does it,” I’ll offer a clinician’s perspective: I hear that line right before someone shows me a lab panel that looks like a storm warning.

2.4 Experimental / emerging uses

Research never stops, and that includes compounds that attract performance interest. A few examples:

• HIF stabilizers (hypoxia-inducible factor prolyl hydroxylase inhibitors) are being studied and used in some regions for anemia in chronic kidney disease. They influence endogenous erythropoietin pathways. The performance misuse risk is obvious, but long-term safety and appropriate patient selection remain central medical questions.
• SARMs (selective androgen receptor modulators) are widely marketed online as “safer steroids.” That claim is not supported by robust long-term clinical safety data for non-medical use. Clinically, they remain investigational for most contexts, and quality control in the gray market is notoriously unreliable.
• Peptides marketed for “recovery” or “fat loss” often sit in a fog of limited evidence, variable purity, and aggressive claims. I’ve seen patients assume “peptide” means “gentle.” Chemistry doesn’t care about branding.

For a deeper look at how clinicians evaluate evidence quality and risk, you might find our section on research useful.

Risks and side effects

Side effects are not a moral punishment; they’re predictable physiology. The risk profile depends on the drug class, dose, duration, route, underlying health, and—this is the part people hide—what else is being taken at the same time. Stacks and cycles turn clean pharmacology into chaos.

3.1 Common side effects

Anabolic-androgenic steroids commonly cause acne, oily skin, hair loss in genetically susceptible individuals, fluid retention, and mood changes. Libido can swing in either direction. Sleep can worsen. In women, virilizing effects such as voice deepening and increased body hair can occur and can be irreversible.

Stimulants frequently cause decreased appetite, insomnia, jitteriness, dry mouth, headache, and increased heart rate. People often describe feeling “locked in” at first, then increasingly irritable or anxious. The crash is real. So is the temptation to chase it with more.

ESAs can cause hypertension and flu-like symptoms, and they raise hematocrit—sometimes beyond safe targets if misused. Beta-2 agonists often cause tremor, palpitations, and anxiety, particularly at higher-than-prescribed doses. Growth hormone commonly leads to edema, joint aches, and numbness/tingling consistent with nerve compression symptoms.

Most of these symptoms start as “annoying.” People ignore them. That’s how the story usually begins.

3.2 Serious adverse effects

Serious harms are less common than mild side effects, but they’re the reason clinicians are cautious.

• Cardiovascular events: elevated blood pressure, arrhythmias, cardiomyopathy, heart attack, and stroke have been associated with stimulant misuse and with anabolic steroid use, especially with prolonged exposure and in those with underlying risk factors.
• Thrombotic complications: ESAs and any practice that increases red cell mass can increase clot risk. Thickened blood strains the heart and can contribute to stroke or pulmonary embolism.
• Liver injury: certain oral anabolic steroids (particularly 17-alpha-alkylated compounds) are associated with cholestasis, hepatitis-like injury, and rare liver tumors. “My liver enzymes were only a little high” is a sentence I’ve heard right before a much worse lab result.
• Endocrine shutdown and infertility: exogenous androgens suppress the hypothalamic-pituitary-gonadal axis, reducing testicular function and sperm production. Recovery is unpredictable.
• Psychiatric effects: severe anxiety, agitation, paranoia, and depressive episodes can occur with stimulants and with androgen misuse. Patients tell me, quietly, that the relationship damage came before the medical damage.

Seek urgent medical attention for chest pain, fainting, severe shortness of breath, sudden one-sided weakness, severe headache with neurologic symptoms, confusion, or suicidal thoughts. Those are not “side effects to push through.”

3.3 Contraindications and interactions

Contraindications vary by drug class, but several patterns repeat.

• Stimulants are risky in uncontrolled hypertension, certain arrhythmias, structural heart disease, and in people with significant anxiety or substance use disorders. They interact with other sympathomimetics (including many pre-workout products) and can be dangerous with MAO inhibitors.
• Anabolic steroids/testosterone require careful evaluation in those with prostate cancer, breast cancer (in men), severe untreated sleep apnea, polycythemia, or uncontrolled heart failure. They can interact with anticoagulants and can worsen lipid profiles, compounding cardiovascular risk.
• PDE5 inhibitors (e.g., sildenafil) have a well-known dangerous interaction with nitrates (used in angina) and can cause severe hypotension when combined. They also interact with certain alpha-blockers and medications that affect CYP3A4 metabolism.
• Beta-2 agonists can compound tachycardia and hypokalemia risk, especially when combined with diuretics or other stimulants.

Alcohol deserves its own mention. It doesn’t “cancel out” stimulants; it often hides impairment and encourages risk-taking. Mixing alcohol with stimulants is a classic recipe for overexertion and poor judgment—two things the emergency department sees plenty of.

Beyond medicine: misuse, myths, and public misconceptions

This is the section where people expect a lecture. They won’t get one from me. What I’ll give you is what I see: a lot of smart, motivated people making surprisingly casual decisions about potent pharmacology. The internet normalizes it. Social media glamorizes it. And counterfeit supply chains make it even more dangerous than it used to be.

4.1 Recreational or non-medical use patterns

Non-medical use tends to cluster into a few familiar goals: faster muscle gain (AAS/SARMs), rapid fat loss (stimulants, thyroid hormone misuse, beta-agonists), endurance boosts (ESAs, stimulants), and sexual performance (PDE5 inhibitors). The expectations are often inflated because the loudest voices online are the outliers: genetically gifted responders, people using multiple drugs, or people selling an image.

In my experience, the most common misconception is that side effects are optional. They aren’t. Another common pattern: people self-diagnose “low testosterone” based on fatigue alone, then treat themselves with underground products without ever checking levels, sleep, depression, alcohol use, or metabolic health. That’s not optimization. That’s guessing.

4.2 Unsafe combinations

Stacking is where risk accelerates. Combining stimulants with beta-agonists can push heart rate and blood pressure into unsafe territory. Adding diuretics for “dryness” can worsen electrolyte imbalances and provoke arrhythmias. Pairing ESAs with dehydration, altitude exposure, or long-haul travel can compound clot risk. And mixing PDE5 inhibitors with nitrates or “poppers” (amyl nitrite) can cause profound hypotension.

People ask, “What’s the worst that can happen?” The more honest question is: “What’s the worst that can happen quietly?” A clot doesn’t announce itself until it does. Cardiomyopathy can develop gradually. Liver injury can smolder. That’s why clinicians insist on monitoring when these drugs are used medically.

4.3 Myths and misinformation

• Myth: “If it’s a prescription drug, it’s safe.”
  Reality: Prescription status means it has a defined medical use and known risks under supervision. It does not mean it’s safe for non-medical goals.
• Myth: “SARMs are basically side-effect free.”
  Reality: Reports of liver injury, lipid changes, testosterone suppression, and mislabeled products are persistent concerns. Lack of long-term data is not proof of safety.
• Myth: “Testosterone is just ‘replacement,’ so higher is better.”
  Reality: Physiologic replacement aims for normal ranges. Supraphysiologic exposure shifts the risk-benefit balance and increases adverse effects.
• Myth: “EPO is only dangerous if you’re old or sick.”
  Reality: Increasing hematocrit increases viscosity and clot risk regardless of age, especially when combined with dehydration or other stressors.

If you’re interested in the psychology behind risk-taking and body image pressure, our section on psychological wellness connects a lot of dots.

Mechanism of action (plain-English physiology)

Because “performance enhancement drugs” is a broad label, the mechanisms differ. Still, a few core pathways explain most effects.

Anabolic-androgenic steroids and testosterone work primarily by binding the androgen receptor inside cells. That receptor then influences gene transcription—essentially changing which proteins a cell builds. In muscle, this shifts the balance toward protein synthesis and away from breakdown, especially when combined with resistance training and adequate nutrition. Androgens also affect red blood cell production, libido, sebaceous glands (hello, acne), and the central nervous system. That’s why the effects are not limited to muscle.

ESAs act like (or stimulate) erythropoietin, a hormone that signals the bone marrow to produce more red blood cells. More red cells can increase oxygen delivery. The catch is that blood becomes more viscous as hematocrit rises, increasing strain on the cardiovascular system and raising clot risk—particularly when targets are pushed beyond medical guidelines.

Stimulants increase signaling of neurotransmitters such as dopamine and norepinephrine in key brain circuits. In ADHD, that can normalize attention networks. In people without ADHD—or when doses are escalated—those same pathways can produce overstimulation: insomnia, anxiety, elevated heart rate, and impaired judgment dressed up as confidence.

Growth hormone (somatropin) increases IGF-1 production (mainly in the liver) and influences metabolism, fluid balance, and tissue growth signals. That does not translate neatly into “pure muscle gain.” The body’s adaptive response is complex, and side effects like edema and insulin resistance reflect that complexity.

PDE5 inhibitors (sildenafil) block the enzyme phosphodiesterase-5, increasing cGMP signaling in smooth muscle and promoting vasodilation in specific vascular beds, including penile tissue. This supports erectile function in response to sexual stimulation; it does not create desire, fix relationship stress, or override severe vascular disease.

Historical journey

6.1 Discovery and development

The history of performance enhancement drugs is really a set of overlapping histories. Testosterone was isolated and synthesized in the early 20th century, and anabolic steroids followed as chemists modified the molecule to alter anabolic versus androgenic effects and to change oral bioavailability. Their medical promise—treating hypogonadism and catabolic illness—was genuine. Their misuse in sport also arrived early, because the basic idea is obvious: if androgens support muscle and recovery, more must be better. Humans love linear thinking. Physiology rarely cooperates.

Erythropoietin’s story is a classic example of biotechnology changing medicine. Recombinant erythropoietin transformed anemia care for many patients with kidney disease and chemotherapy-related anemia. Not long after, endurance sports faced a new kind of doping—one that could be hard to detect and easy to rationalize. “It’s just more red blood cells” sounds harmless until you understand viscosity and thrombosis.

Sildenafil’s origin story is often misunderstood. It was developed in the context of cardiovascular research and later became famous for erectile dysfunction. That single drug arguably changed public conversation about sexual health more than any public health campaign ever did. Patients who once suffered in silence began asking for help. That part, as a clinician, I consider a win.

6.2 Regulatory milestones

Regulatory approvals for these medications generally followed clear medical needs: hormone replacement, anemia management, asthma control, ADHD treatment, growth hormone deficiency. Separate from approvals, sports governing bodies developed anti-doping rules and testing frameworks as misuse became widespread. The tension has never gone away: medicine aims to treat disease; sport aims to define fair competition; the marketplace aims to sell hope.

6.3 Market evolution and generics

Over time, many of these drugs became available as generics—testosterone formulations, sildenafil, albuterol, and numerous stimulants. Generic availability improves access for patients with legitimate indications. It also changes misuse dynamics, because lower cost and wider distribution can increase non-medical availability. Then there’s the parallel market: underground labs, counterfeit tablets, and mislabeled “research chemicals.” That ecosystem thrives on two things: demand and secrecy.

Society, access, and real-world use

This topic is never just pharmacology. It’s culture, identity, and pressure. I’ve had patients who felt they couldn’t keep up at work without stimulants, couldn’t keep up in the gym without anabolic agents, and couldn’t keep up in relationships without PDE5 inhibitors. That’s a lot of “keeping up.” It’s exhausting just hearing it.

7.1 Public awareness and stigma

Some performance-related conditions carry stigma: erectile dysfunction, infertility, low testosterone symptoms, ADHD, and substance use. Public awareness has improved, but stigma hasn’t vanished; it just changed outfits. Instead of silence, people now self-diagnose on social media. Instead of shame, there’s optimization culture. Patients tell me they feel weak for needing help, then feel weak again for not transforming fast enough once they start treatment. That double bind is rough.

There’s also stigma in the other direction. People who use medically indicated testosterone or stimulants sometimes get treated as if they’re cheating at life. That’s unfair. A diagnosis is not a character flaw, and treatment under supervision is not the same as misuse.

7.2 Counterfeit products and online pharmacy risks

If there’s one real-world issue I wish everyone took more seriously, it’s counterfeit and contaminated products. Online sellers can provide incorrect doses, wrong active ingredients, or no active ingredient at all. Injectable products raise additional risks: non-sterile preparation, bacterial contamination, and local tissue injury. I’ve seen abscesses that started as “just a little swelling,” and I’ve seen lab results that didn’t match what the label promised—because the label was fiction.

Even when the active ingredient is correct, dosing variability and impurities can change side-effect profiles. And without medical monitoring, early warning signs—rising hematocrit, worsening lipids, elevated liver enzymes, blood pressure creep—go unnoticed until a crisis forces attention.

7.3 Generic availability and affordability

Generics are often clinically equivalent to brand-name drugs when sourced through regulated channels, with the same active ingredient and expected bioequivalence standards. For patients, that can mean improved affordability and continuity of care. For clinicians, it can mean fewer barriers to treating real disease. The downside is that the word “generic” gets misused in gray markets to imply legitimacy. A counterfeit tablet is not a generic. It’s a gamble.

7.4 Regional access models (prescription, pharmacist-led, OTC)

Access rules vary widely by country and even by region within a country. Some medications are strictly prescription-only; others have pharmacist-led pathways; a few are available over the counter in certain places. That variability fuels confusion, especially online, where people assume that if a drug is easy to obtain somewhere, it must be safe everywhere. Regulatory categories reflect policy choices, not personal risk profiles.

When patients ask me what “safe access” looks like, I describe a boring process: proper diagnosis, a clear therapeutic goal, screening for contraindications, and follow-up. Boring is good. Boring keeps people out of trouble.

Conclusion

Performance enhancement drugs include medications with real, sometimes life-changing medical value—testosterone for true hypogonadism, stimulants for ADHD, ESAs for specific anemia syndromes, beta-2 agonists for asthma, growth hormone for documented deficiency, and PDE5 inhibitors such as sildenafil for erectile dysfunction and select cardiopulmonary indications. Used correctly, they can restore function and relieve suffering. Used casually, they can create problems that are harder to treat than the original complaint.

The most reliable way to separate fact from hype is to ask three questions: What is the diagnosis? What is the evidence for benefit in that diagnosis? What are the predictable risks in this specific body with this specific medical history? If those questions aren’t being answered, what you have isn’t healthcare—it’s experimentation.

Informational disclaimer: This article is for general education and does not replace individualized medical advice, diagnosis, or treatment. If you’re considering or already using any performance-related medication or supplement, discuss it with a licensed clinician who can review your history, medications, and risks.